Literature DB >> 3033027

Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model.

J P Eder, B A Teicher, S A Holden, K N Cathcart, L E Schnipper.   

Abstract

DNA-DNA crosslinks are the lethal cellular mechanism of bifunctional alkylating agent cytotoxicity. Novobiocin, an inhibitor of DNA topoisomerase II, impairs eukaryotic DNA repair of alkylating agent adducts and may increase the number of adducts and their resultant cytotoxicity in malignant cells. The effect of novobiocin on clonogenic survival and DNA crosslinking due to cisplatin (cDDP) and carmustine (BCNU) was studied. Novobiocin caused synergistic cytotoxicity in Chinese hamster ovary cells exposed to cDDP or BCNU. Novobiocin and cDDP increased the formation of DNA-DNA interstrand crosslinks six-fold greater than cDDP alone. The effect was schedule dependent. Novobiocin and cDDP or BCNU markedly reduced in vivo growth of a murine fibrosarcoma without increased host toxicity. As a modulating agent of cytotoxicity due to DNA-DNA crosslinking, novobiocin may enhance the clinical effectiveness of the alkylating agents in human cancer and offer insight into new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3033027      PMCID: PMC424429          DOI: 10.1172/JCI112983

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

Review 1.  Repair deficient human disorders and cancer.

Authors:  R B Setlow
Journal:  Nature       Date:  1978-02-23       Impact factor: 49.962

Review 2.  Synergy, additivism and antagonism in immunosuppression. A critical review.

Authors:  M C Berenbaum
Journal:  Clin Exp Immunol       Date:  1977-04       Impact factor: 4.330

3.  Radiosensitization with 5-bromodeoxyuridine of Chinese hamster cells x-irradiated during different phases of the cell cycle.

Authors:  W C Dewey; L E Stone; H H Miller; R E Giblak
Journal:  Radiat Res       Date:  1971-09       Impact factor: 2.841

4.  DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum(II) and L-phenylalanine mustard.

Authors:  L A Zwelling; S Michaels; H Schwartz; P P Dobson; K W Kohn
Journal:  Cancer Res       Date:  1981-02       Impact factor: 12.701

5.  Novobiocin inhibition of simian virus 40 DNA replication.

Authors:  H J Edenberg
Journal:  Nature       Date:  1980-07-31       Impact factor: 49.962

6.  Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break.

Authors:  L F Liu; C C Liu; B M Alberts
Journal:  Cell       Date:  1980-03       Impact factor: 41.582

7.  Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity.

Authors:  G G Steel; M J Peckham
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-01       Impact factor: 7.038

8.  Isobologram analysis of X-ray--BCNU interactions in vitro.

Authors:  D F Deen; M E Williams
Journal:  Radiat Res       Date:  1979-09       Impact factor: 2.841

9.  DNA cross-linking by in vivo treatment with 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea of sensitive and resistant human colon carcinoma xenograms in nude mice.

Authors:  C B Thomas; R Osieka; K W Kohn
Journal:  Cancer Res       Date:  1978-08       Impact factor: 12.701

Review 10.  Curative cancer chemotherapy.

Authors:  E Frei
Journal:  Cancer Res       Date:  1985-12       Impact factor: 12.701

View more
  8 in total

Review 1.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

2.  Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.

Authors:  G N Schwartz; B A Teicher; J P Eder; T Korbut; S A Holden; G Ara; T S Herman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline.

Authors:  J P Eder; B A Teicher; S A Holden; L Senator; K N Cathcart; L E Schnipper
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  A DNA topoisomerase II-independent route for novobiocin-mediated resistance to DNA binding agents.

Authors:  P J Smith; S M Bell
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.

Authors:  B A Teicher; S A Holden; V Khandakar; T S Herman
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

6.  Novobiocin modulates colchicine sensitivity in parental and multidrug-resistant B16 melanoma cells.

Authors:  J Nordenberg; J Kornfeld; L Wasserman; M Shafran; E Halabe; E Beery; O Landau; A Novogrodsky; Y Sidi
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 7.  Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

Authors:  H Timmer-Bosscha; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

8.  Novobiocin-induced anti-proliferative and differentiating effects in melanoma B16.

Authors:  J Nordenberg; D Albukrek; T Hadar; A Fux; L Wasserman; A Novogrodsky; Y Sidi
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.